Raymond James & Associates Red Hill Biopharma Ltd. Transaction History

Raymond James & Associates

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 11, 2021	SELL	$5.98 - $7.51 $198,787 - $249,647	-33,242 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$6.98 - $11.29 $76,082 - $123,060	-10,900 Reduced 24.69%	33,242 $243,000
Q4 2020 Feb 12, 2021	BUY	$7.81 - $10.39 $200,264 - $266,420	25,642 Added 138.61%	44,142 $357,000
Q3 2020 Nov 04, 2020	BUY	$6.34 - $10.83 $117,290 - $200,355	18,500 New	18,500 $189,000

40.4K

Ticker RDHL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 63,823,500
Market Cap $465M
Description
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.